Ivonescimab

Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: Current treatment options and standard of care
Published: 2026-09-14T15:39:06-04:00

EGFR-mutated non-small-cell lung cancer

Manufacturer: Summit Therapeutics
Regulatory submission: BLA submitted in the fourth quarter of 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

12 evidence topics · 9 sources

EGFR tyrosine kinase inhibitors1 evidence topic · 2 sources
Platinum-based chemotherapy1 evidence topic · 1 source
EGFR/MET bispecific antibodies2 evidence topics · 2 sources
Antibody-drug conjugates1 evidence topic · 1 source
Antiangiogenic combination therapy2 evidence topics · 2 sources
Surgical resection1 evidence topic · 1 source
Radiotherapy1 evidence topic · 1 source
Supportive and palliative care1 evidence topic · 2 sources
Limitations of current therapies2 evidence topics · 4 sources